Muscle pain prophylaxis.

Muscle pain prophylaxis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Muscle pain prophylaxis. Abstract Text:

G A Dudley,

Most individuals experience muscle soreness one or two days following novel physical activity such as the first down-hill, snow skiing trip of the season. This arises from forced lengthening of skeletal muscles fibers while they are active, for example, as the skier absorbs the shock of each mogul she/he encounters. Some muscle fibers are injured, force is reduced and an inflammatory response ensues. Muscle proteins are released into the blood, force may further decrease, the injured muscle swells due to edema and soreness increases. These responses reach their peak lowest point within several days of exercise and generally subside within a week. Scientists have developed models which emphasize forced lengthening of skeletal muscle in an effort to study exercise induced muscle injury and the subsequent delayed onset muscle soreness (DOMS) in detail. Several of these studies have examined the efficacy of anti-inflammatory drugs (AIDs) for treatment of the muscle injury and DOMS. The results of some, but not all, of these studies suggest that non-steriodal AIDs (NSAIDs) attenuate muscle injury and perceived soreness while hastening strength recovery. It also appears that NSAIDs attenuate gait disturbances in older individuals evoked by novel, lengthening muscle actions. Future studies need to assess the effect of novel physical activity upon functional capacity as influenced by NSAIDs in older and/or inactive individuals who seem especially vulnerable to contraction induced muscle fiber injury.

Muscle pain prophylaxis. Publishing Authors By Initials

GA Dudley,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Muscle pain prophylaxis. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Inflammopharmacology

VOLUME: 7

Page Numbers: 249-53

Journal Abbreviation:

ISSN: 0925-4692

DAY: 19

MONTH: 07

YEAR: 1999

Muscle pain prophylaxis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9112626

Muscle pain prophylaxis. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Muscle pain prophylaxis. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Muscle pain prophylaxis.

AFFILIATION: Department of Exercise Science, The University of Georgia, 115 M Ramsey Center, 300 River Road, 30602, Athens, GA, USA, gdudley@coe.uga.edu.

Country: Switzerland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Inflammopharmacology

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Muscle pain prophylaxis Related Publications

• 'Rules of thumb' or reflective practice? Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation.
• A Boisen reverie.
• A sodium channel pore mutation causing Brugada syndrome.
• A tandem carbanion addition/carbon-carbon bond cleavage yields alkynyl ketones.
• A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improved myocardial remodeling.
• ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer.
• Cardiac-restricted angiotensin-converting enzyme overexpression causes conduction defects and connexin dysregulation.
• Characterization of green fluorescent protein-expressing retinal cells in CD 44-transgenic mice.
• Determination of gallium in biological materials.
• Diabetic-associated stillbirth: incidence, pathophysiology, and prevention.
• Early determinants of H2O2-induced endothelial dysfunction.
• Endogenous MMTV proviruses induce susceptibility to both viral and bacterial pathogens.
• Generation and characterization of 0.6-THz polarization domain-wall trains in an ultralow-birefringence spun fiber.
• Human heart failure is associated with abnormal C-terminal splicing variants in the cardiac sodium channel.
• Identifying widely covered drugs and drug coverage variation among Medicare part D formularies.
• Mosaicism in autosomal dominant polycystic kidney disease revealed by genetic testing to enable living related renal transplantation.
• Muscle pain prophylaxis.
• Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias.
• Optimization of apodization functions in terahertz transient spectrometry.
• Oxidative stress markers are associated with persistent atrial fibrillation.
• Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a Neutropenic Mouse Thigh Infection Model.
• Physiological Responses of Combining Electrical Stimulation of the Thighs with Voluntary Arm Exercise on the NuStep(R): 2549: Board #96 June 2 9:30 AM - 11:00 AM.
• Post stroke fatigue--where is the evidence to guide practice?
• Prediction of Atrial Fibrillation following Cardiac Surgery using Rough Set Derived Rules.
• Skeletal muscle atrophy and increased intramuscular fat after incomplete spinal cord injury.
• Skin bacteria and Op Site((R)) chest dressings.
• Sustaining evidence-based practice for young people who self-harm: a 4-year follow-up.
• Synthesis of benzyl esters using 2-benzyloxy-1-methylpyridinium triflate.
• Use of trifluoroacetic acid to quantify small, polar compounds in rat plasma during discovery-phase pharmacokinetic evaluation.
• Variable-frequency-train stimulation of skeletal muscle after spinal cord injury.